Argenx stock gains on Forte Biosciences deal and strong growth outlook

Published on 09/20/2026 at 14:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock closed at USD 990.32 on September 18, 2026 on Nasdaq, up 17.8% year to date and around 30% over the last 12 months. Recent analyst commentary highlights consensus upside of about 20% with some targets more than 40% above the current price.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) finished Nasdaq trading at USD 990.32 on September 18, 2026, reflecting a gain of 17.8% since the start of 2026 and about 30% over the last 12 months per data cited in a recent analyst overview. As MarketBeat reports in its latest summary updated on September 19, 2026, the shares trade with a market capitalization of about USD 61.95 billion and remain below the consensus 12-month price target, indicating further upside potential.

Forte Biosciences acquisition reshapes Argenx pipeline

A key catalyst for Argenx stock around September 20, 2026 is the agreed acquisition of Forte Biosciences, an immunology-focused biotechnology company, in an all-cash transaction valued at approximately USD 2.2 billion. According to Stocktwits News on September 20, 2026, Forte Biosciences shareholders are set to receive USD 77 per share, and Forte stock surged to a four-year high of USD 76.60 on the announcement.

The USD 2.2 billion deal price implies a modest premium to the USD 77 per share consideration relative to the four-year high of USD 76.60, underlining investors' confidence that Argenx can unlock value from Forte's immunology assets. In the same report, Stocktwits News notes that Evercore ISI reacted by downgrading Forte Biosciences to In Line from Outperform and raising its price target to USD 77 from USD 69, aligning its target with the agreed takeover price.

Revenue growth and analyst consensus support valuation

Beyond the Forte Biosciences transaction, Argenx continues to be characterized by sustained top-line growth in its core antibody-based therapies for severe autoimmune diseases. As MarketBeat highlights in its argenx company overview updated on September 19, 2026, the company has delivered 18 consecutive quarters of sales growth, an unusual streak for a biotech focused on autoimmune indications.

While the MarketBeat summary does not break out individual quarterly revenue figures in detail, the period of 18 straight growth quarters implies at least four and a half years of continuous year-over-year expansion, meaning Argenx has increased sales every quarter from fiscal 2022 through the latest reported quarter within the nine-month freshness window before September 20, 2026. This consistency and the fact that the shares are up 17.8% year to date from USD 840.95 at the beginning of 2026 to USD 990.32 by the September 18, 2026 close, as noted by MarketBeat, underscore how revenue growth is being reflected in the share price.

Analyst sentiment remains constructive. The same MarketBeat overview reports a consensus rating of Moderate Buy for Argenx based on 2 strong buy ratings, 17 buy ratings and 5 hold ratings, with no sell recommendations. According to MarketBeat on September 19, 2026, the consensus 12-month price target stands at USD 1,158.61, representing about 17% upside from the USD 990.32 closing price on September 18, 2026.

Some banks see more than 40 percent upside

Recent commentary from individual Wall Street analysts suggests that upside could be higher than the consensus. In a detailed article dated September 20, 2026, The Motley Fool reports that Wells Fargo analyst Derek Archila and UBS analyst Xian Deng both assign 12-month price targets for Argenx more than 40% above the current share price.

In that analysis, The Motley Fool notes that the consensus one-year price target reflects upside of around 20%, but these two analysts project that Argenx shares can rise more than 40% over the next 12 months, implying that their individual targets are at least USD 1,386 when applied to the USD 990.32 reference price.

The article also reiterates that Argenx shares have risen roughly 30% over the last 12 months, illustrating that the stock has already delivered strong performance yet is still viewed as undervalued by some analysts relative to its growth prospects. For investors, the spread between the consensus target of USD 1,158.61 and the more aggressive implied targets above USD 1,386 marks a clear quantified range of expectations that can be weighed against Argenx's pipeline execution and integration of Forte Biosciences.

Risks: valuation, margins and execution after the deal

The strength of Argenx's share price, its P/E ratio and the size of the Forte Biosciences acquisition naturally raise questions about valuation and execution risk. MarketBeat lists a P/E ratio of 38.03 for Argenx based on its current price and trailing earnings, as shown in the argenx profile updated September 19, 2026, implying that investors are paying just over 38 times recent earnings for exposure to its autoimmune antibody portfolio and growth path.

That multiple stands against the backdrop of 18 consecutive quarters of sales growth, but any slowdown in revenue or margin pressure arising from the integration of Forte Biosciences could compress the valuation. Moreover, the USD 2.2 billion all-cash outlay for Forte Biosciences and the raised USD 77 price target from USD 69 at Evercore ISI, highlighted by Stocktwits News, show the market is already capitalizing much of Forte's value into the deal price.

For Argenx shareholders, this means the key risk factor is whether the company can generate incremental revenue and earnings from Forte's assets that justify both the acquisition premium and the rich earnings multiple. Any delay in clinical milestones, regulatory approvals or commercialization timelines for the combined pipeline could narrow the currently projected 17% consensus upside and challenge the more optimistic forecasts of greater than 40% share-price appreciation over the next 12 months.

Stock holds near upper end of recent range

From a trading perspective, Argenx stock is currently positioned near the upper end of its recent price channel. A quantitative signals report dated September 19, 2026 from StockTradersDaily lists near-term support signals around USD 979.36 and resistance signals around USD 994.03, with the current price highlighted at USD 990.32 inside a mid-channel oscillation pattern.

Per that same quantitative analysis from StockTradersDaily, the long-term resistance signal sits at USD 1,006.42 versus long-term support at USD 904.36, suggesting that Argenx shares are trading closer to the upper end of their recent technical range than to support. For investors, the combination of a USD 990.32 closing price on September 18, 2026, consensus fundamental upside of roughly 17% to USD 1,158.61 and potential technical resistance just above USD 1,000 illustrates a market that is already pricing in a meaningful portion of expected growth yet still leaves room for further gains if Argenx executes its strategy and the Forte Biosciences acquisition delivers on its promise.